Observational Data With Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist May Not Reflect Current Practice With Single Triple Inhalers Response

被引：0
|
作者：
Suissa, Samy
Ernst, Pierre
机构：
[1] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
[2] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
来源：
CHEST | 2020年 / 157卷 / 04期
关键词：
D O I：
10.1016/j.chest.2019.12.030
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1045 / 1046
页数：4
相关论文
共 50 条
  • [1] Switching from long-acting beta-agonist and inhaled corticosteroid to long-acting beta-agonist and long-acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal
    Lam, Jamie Chung Mei
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 15 - 18
  • [2] Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
    Yuasa, Mizuki
    Tanaka, Yosuke
    Tanaka, Tohru
    Kashiwada, Takeru
    Taniuchi, Namiko
    Saito, Yoshinobu
    Seike, Masahiro
    Hino, Mitsunori
    Gemma, Akihiko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [3] Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for COPD: A systematic review and meta-analysis
    Horita, Nobuyuki
    Miyazawa, Naoki
    Tomaru, Koji
    Inoue, Miyo
    Kaneko, Takeshi
    RESPIROLOGY, 2015, 20 (08) : 1153 - 1159
  • [4] Cost Effectiveness of Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist (ICS/LABA/LAMA) Coverage Related to Reduction in Risk of Exacerbations
    White, J.
    Szema, A. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [5] Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
    Eung Gu Lee
    Youlim Kim
    Yong Il Hwang
    Kwang Ha Yoo
    So Eun Lee
    Kyung Yoon Jung
    Doik Lee
    Yong Bum Park
    Chin Kook Rhee
    Scientific Reports, 13
  • [6] Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
    Lee, Eung Gu
    Kim, Youlim
    Hwang, Yong Il
    Yoo, Kwang Ha
    Lee, So Eun
    Jung, Kyung Yoon
    Lee, Doik
    Park, Yong Bum
    Rhee, Chin Kook
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] Efficacy and Safety of Long-Acting β-Agonist/Long-Acting Muscarinic Antagonist Combinations Compare to Long-Acting β-Agonist/Inhaled Corticosteroid Combinations: A Network Meta-Analysis
    Ahmed, T. Said
    Al-Sarie, M.
    Srour, K.
    Rygielski, S.
    Ye, F.
    Hernandez, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [8] Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype
    Lee, Ji-Hyun
    Lee, Young Kyung
    Kim, Eun-Kyung
    Kim, Tae-Hyung
    Huh, Jin Won
    Kim, Woo Jin
    Lee, Jin Hwa
    Lee, Sang-Min
    Lee, Sangyeub
    Lim, Seong Yong
    Shin, Tae Rim
    Yoon, Ho Il
    Sheen, Seung Soo
    Kim, NamKug
    Seo, Joon Beom
    Oh, Yeon-Mok
    Do Lee, Sang
    RESPIRATORY MEDICINE, 2010, 104 (04) : 542 - 549
  • [9] Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis
    Oba, Yuji
    Chandran, Arul V.
    Devasahayam, Joe V.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 13 (06) : 677 - 685
  • [10] Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
    Fukuda, Nobuhiko
    Horita, Nobuyuki
    Kaneko, Ayami
    Goto, Atsushi
    Kaneko, Takeshi
    Ota, Erika
    Kew, Kayleigh M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (06):
12345